Relapsing-remitting Multiple Sclerosis
📧 Sign up to get email alerts when something new happens for Relapsing-remitting Multiple Sclerosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2021-03-08Clinical Trial Update: Patient Research Cohort: Rapidly Evolving Multiple Sclerosis
A completed clinical trial update from Imperial College London on a patient research cohort for Relapsing-remitting and Secondary Progressiv…
-
CLINICAL_TRIALS trial_result · 2021-02-05Clinical Trial Update: A Study of Efficacy and Safety of M2951 in Participants With Relapsing Multiple Sclerosis [Phase 2]
Phase 2 study of M2951 in relapsing-remitting multiple sclerosis was terminated, with results posted in 2021.
-
CLINICAL_TRIALS trial_result · 2021-02-03Clinical Trial Update: A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT) [Phase 3]
A Phase 3 clinical trial evaluating ocrelizumab in relapsing-remitting multiple sclerosis patients with suboptimal response to prior disease…
-
CLINICAL_TRIALS trial_result · 2020-12-31Clinical Trial Update: BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS) [Phase 3]
Phase 3 extension study assessing BG00012 monotherapy safety and efficacy in relapsing-remitting multiple sclerosis has completed with resul…
-
CLINICAL_TRIALS trial_result · 2020-11-25Clinical Trial Update: Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current Therapy [Phase 4]
Phase 4 trial update evaluating safety and tolerability in Portuguese participants with relapsing-remitting multiple sclerosis transitioning…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2020-11-09Clinical Trial Update: Biological Activity and Safety of Low Dose IL2 in Relapsing Remitting Multiple Sclerosis [Phase 2]
Phase 2 trial updating the biological activity and safety of low-dose interleukin-2 in relapsing multiple sclerosis.
-
CLINICAL_TRIALS trial_result · 2020-09-01Clinical Trial Update: Tolerability of Acthar for the Treatment of Multiple Sclerosis in Relapses (TAMS) [NA]
Clinical trial update on tolerability of Acthar for treating relapses in Relapsing Remitting Multiple Sclerosis; study completed with result…
-
CLINICAL_TRIALS trial_result · 2020-07-14Clinical Trial Update: A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2 [Phase 3]
Phase 3 tolerability study in relapsing remitting multiple sclerosis (RRMS) completed; results posted.
-
CLINICAL_TRIALS trial_result · 2020-03-19Clinical Trial Update: A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes [Phase 4]
Phase 4 trial update evaluating Tecfidera (dimethyl fumarate) on multiple sclerosis disease activity and patient-reported outcomes has compl…
-
CLINICAL_TRIALS trial_result · 2020-03-02Clinical Trial Update: A 3-year Multi-center Study to Describe Changes of OCT Parameters Under Treatment With Gilenya® [Phase 4]
A Phase 4 trial updating OCT parameter changes in patients with Relapsing Remitting Multiple Sclerosis treated with Gilenya (fingolimod).
-
CLINICAL_TRIALS trial_result · 2020-02-25Clinical Trial Update: Safety, Tolerability And Mechanism Of Action Of Boswellic Acids (BA) In Multiple Sclerosis (SABA) [Phase 2]
Phase 2 trial update evaluating safety, tolerability and mechanism of action of boswellic acids in relapsing remitting multiple sclerosis.
-
CLINICAL_TRIALS trial_result · 2020-01-21Clinical Trial Update: Autologous Mesenchymal Stromal Cells for Multiple Sclerosis [Phase 1, Phase 2]
Phase 1/2 trial assessing autologous mesenchymal stromal cells in relapsing-remitting and secondary progressive multiple sclerosis has compl…
-
CLINICAL_TRIALS trial_result · 2020-01-13Clinical Trial Update: Plegridy Satisfaction Study in Participants [Phase 4]
Phase 4 trial update for Plegridy in participants with relapsing-remitting multiple sclerosis has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2020-01-13Clinical Trial Update: Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis [Phase 2]
Phase 2 study assessing safety, tolerability, efficacy, and optimal dosing of BAF312 in relapsing-remitting multiple sclerosis has completed…
-
CLINICAL_TRIALS trial_result · 2019-12-04Clinical Trial Update: Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019 [Phase 3]
Long-term extension study in multiple sclerosis participants completed following a prior trial; terminated with results posted in 2019.
-
CLINICAL_TRIALS trial_result · 2019-11-22Clinical Trial Update: Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) [Phase 3]
Phase 3 extension study in pediatric relapsing-remitting multiple sclerosis completed; results posted in 2019.
-
CLINICAL_TRIALS trial_result · 2019-11-06Clinical Trial Update: Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition [Phase 2]
Phase 2 trial evaluating estriol treatment for cognitive effects in multiple sclerosis patients.
-
CLINICAL_TRIALS trial_result · 2019-10-31Clinical Trial Update: Fingolimod Versus Dimethyl-fumarate in Multiple Sclerosis [Phase 4]
A Phase 4 trial comparing fingolimod to dimethyl fumarate in relapsing-remitting multiple sclerosis was terminated.
-
CLINICAL_TRIALS trial_result · 2019-10-30Clinical Trial Update: A Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity in Patients With Relapsing-remitting Multiple Sclerosis [Phase 2]
Phase 2 trial evaluating a single infusion of VAY736 in relapsing-remitting multiple sclerosis; study terminated with posted results.
-
CLINICAL_TRIALS trial_result · 2019-09-30Clinical Trial Update: Fingolimod Effect on Cytokine and Chemokine Levels [Phase 4]
Phase 4 clinical trial evaluating fingolimod effects on cytokine and chemokine levels in relapsing remitting multiple sclerosis completed wi…
-
CLINICAL_TRIALS trial_result · 2019-09-24Clinical Trial Update: Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab [Phase 3]
Phase 3 trial evaluating efficacy and safety of daclizumab in RRMS patients switching from natalizumab; study terminated with posted results…
-
CLINICAL_TRIALS trial_result · 2019-07-18Clinical Trial Update: Glatiramer Acetate (Copaxone®) Study to Follow Participants From the First Original Study for Safety and Effectiveness [Phase 4]
Phase 4 trial update following participants from the original study to assess safety and effectiveness of glatiramer acetate (Copaxone) in r…
-
CLINICAL_TRIALS trial_result · 2019-06-27Clinical Trial Update: Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS). [Phase 3]
Phase 3 trial update assessing BG00012 effects on lymphocyte subsets and immunoglobulins in relapsing-remitting multiple sclerosis; study co…
-
CLINICAL_TRIALS trial_result · 2019-05-28Clinical Trial Update: MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone [Phase 3]
Phase 3 trial comparing two doses of fingolimod to Copaxone in relapsing-remitting multiple sclerosis was terminated with posted results.
-
CLINICAL_TRIALS trial_result · 2019-03-27Clinical Trial Update: An Extension Study of LAQ/5062 Exploring the Long Term Safety, Tolerability and Clinical Effect Parameters During the Disease [Phase 2]
Phase 2 extension study evaluating long-term safety and tolerability of LAQ/5062 in relapsing remitting multiple sclerosis was terminated wi…